REG - Morgan Stanley & Co. Oxford Biomedica PLC - Form 8.5 (EPT/RI) - Oxford Biomedica plc
02/02/2026 10:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260202:nRSB3075Ra&default-theme=true
RNS Number : 3075R Morgan Stanley & Co. Int'l plc 02 February 2026
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED
INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader: Morgan Stanley & Co. International plc
(b) Name of offeror/offeree in relation to whose relevant securities this form Oxford Biomedica plc
relates:
Use a separate form for each offeror/offeree
(c) Name of the party to the offer with which exempt principal trader is EQT Fund Management S.a.r.l.
connected:
(d) Date dealing undertaken: 30 January 2026
(e) In addition to the company in 1(b) above, is the exempt principal trader N/A
making disclosures in respect of any other party to this offer?
If it is a cash offer or possible cash offer, state "N/A"
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security Purchases/ sales Total number of securities Highest price per unit paid/received Lowest price per unit paid/received
50p ordinary SALES 30,714 8.4500 GBP 8.3100 GBP
50p ordinary PURCHASES 31,197 8.4562 GBP 8.3099 GBP
(b) Cash-settled derivative transactions
Class of relevant security Product description Nature of dealing Number of reference securities Price per unit
e.g. CFD e.g. opening/closing a long/short position, increasing/reducing a long/short
position
50p ordinary CFD increasing a long position 2,333 8.3100 GBP
50p ordinary CFD increasing a long position 45 8.3100 GBP
50p ordinary CFD increasing a long position 201 8.4316 GBP
50p ordinary CFD increasing a short position 1,778 8.3100 GBP
50p ordinary CFD increasing a short position 27,052 8.3100 GBP
50p ordinary CFD increasing a short position 2,318 8.3100 GBP
50p ordinary CFD increasing a short position 98 8.3100 GBP
50p ordinary CFD increasing a short position 545 8.3100 GBP
50p ordinary CFD increasing a short position 15,000 8.3100 GBP
50p ordinary CFD increasing a short position 75 8.3833 GBP
50p ordinary CFD increasing a short position 10 8.4000 GBP
50p ordinary CFD increasing a short position 542 8.4184 GBP
50p ordinary CFD reducing a long position 308 8.3100 GBP
50p ordinary CFD reducing a long position 65 8.3100 GBP
50p ordinary CFD reducing a long position 4,248 8.3100 GBP
50p ordinary CFD reducing a long position 1,115 8.3335 GBP
50p ordinary CFD reducing a long position 68 8.3615 GBP
50p ordinary CFD reducing a long position 1,677 8.3837 GBP
50p ordinary CFD reducing a long position 136 8.4000 GBP
50p ordinary CFD reducing a long position 217 8.4075 GBP
50p ordinary CFD reducing a long position 617 8.4075 GBP
50p ordinary CFD reducing a long position 31 8.4078 GBP
50p ordinary CFD reducing a long position 348 8.4121 GBP
50p ordinary CFD reducing a long position 655 8.4250 GBP
50p ordinary CFD reducing a short position 545 8.3100 GBP
50p ordinary CFD reducing a short position 15,000 8.3100 GBP
50p ordinary CFD reducing a short position 27,052 8.3100 GBP
50p ordinary CFD reducing a short position 983 8.3106 GBP
50p ordinary CFD reducing a short position 503 8.3930 GBP
50p ordinary CFD reducing a short position 379 8.3994 GBP
50p ordinary CFD reducing a short position 201 8.3994 GBP
50p ordinary CFD reducing a short position 90 8.4062 GBP
50p ordinary CFD reducing a short position 17 8.4100 GBP
50p ordinary CFD reducing a short position 23 8.4500 GBP
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type Expiry date Option money paid/ received per unit
e.g. American, European etc.
N/A N/A N/A N/A N/A N/A N/A N/A
(ii) Exercise
Class of relevant security Product description Exercising/ exercised against Number of securities Exercise price per unit
e.g. call option
N/A N/A N/A N/A N/A
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing Details Price per unit (if applicable)
e.g. subscription, conversion
N/A N/A N/A N/A
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities which may
be an inducement to deal or refrain from dealing entered into by the exempt
principal trader making the disclosure and any party to the offer or any
person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If
there are no such agreements, arrangements or understandings, state "none"
NONE
(b) Agreements, arrangements or understandings relating to
options or derivatives
Details of any agreement, arrangement or understanding, formal or informal,
between the exempt principal trader making the disclosure and any other person
relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant
securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
NONE
Date of disclosure: 02 February 2026
Contact name: Claire Gordon
Telephone number: +44 141 245-8893
Public disclosures under Rule 8 of the Code must be made to a Regulatory
Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation
to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
(http://www.thetakeoverpanel.org.uk) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END FERTTMLTMTIMMLF
Copyright 2019 Regulatory News Service, all rights reservedRecent news on Oxford BioMedica
See all newsRCS - Oxford Biomedica PLC - Launch of viral vector fast-track offering
AnnouncementREG - Oxford Biomedica PLC - Grant of Awards
AnnouncementREG - Oxford Biomedica PLC - Total Voting Rights
AnnouncementREG - Oxford Biomedica PLC - 2026 Annual General Meeting notification
AnnouncementREG - Oxford Biomedica PLC - Preliminary results for the year ended 31 Dec 2025
Announcement